Post-earnings recap
Reported
Thu, Nov 7, 2024
EPS actual
$-0.54
EPS est.
$-0.59
EPS surprise
+8.47%
1-day move
+0.02%
Protagonist Therapeutics reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. However, the lack of revenue figures and guidance may leave investors cautious. The stock's modest rise indicates a mixed reaction as investors digest the earnings details.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | +8.47% |
| Revenue | N/A | N/A | N/A |
Management conveyed a cautious optimism regarding the company's financial health. They emphasized their commitment to advancing their pipeline.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They highlighted ongoing efforts in research and development as a priority.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—